<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>05391536010256</udiDi>
    <basicUdiDi>843659383XIA643NC</basicUdiDi>
    <tradeName>Tasectan AF</tradeName>
    <deviceName>XILAPLUS AF sachets without flavour</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1312070</reference>
    <placedOnMarketCountry>Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-31T19:47:01.432Z</lastUpdated>
  </row>
  <row>
    <udiDi>05944702208850</udiDi>
    <basicUdiDi>805574884FTKMDR14ET</basicUdiDi>
    <tradeName>Kebene Pro Baby</tradeName>
    <deviceName>COMIL</deviceName>
    <manufacturerName>Gruppo Farmaimpresa srl</manufacturerName>
    <manufacturerSrn>IT-PR-000036632</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.K.MDR.14.5</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-31T19:10:01.471Z</lastUpdated>
  </row>
  <row>
    <udiDi>05011417807187</udiDi>
    <basicUdiDi>7649993626FT42306VN</basicUdiDi>
    <tradeName>Fybocalm Wind &amp; Bloating relief</tradeName>
    <deviceName>Sectacol</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C12B02E030</reference>
    <placedOnMarketCountry>Northern Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-31T18:59:10.154Z</lastUpdated>
  </row>
  <row>
    <udiDi>05011417807170</udiDi>
    <basicUdiDi>7649993626FT42301VC</basicUdiDi>
    <tradeName>Fybocalm Diarrhoea Relief</tradeName>
    <deviceName>Gelsectan</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C05B02E030</reference>
    <placedOnMarketCountry>Northern Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-31T18:59:06.964Z</lastUpdated>
  </row>
  <row>
    <udiDi>05011417807163</udiDi>
    <basicUdiDi>7649993626FT42307VQ</basicUdiDi>
    <tradeName>Fybocalm Constipation relief</tradeName>
    <deviceName>Gelselax</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C20B02E030</reference>
    <placedOnMarketCountry>Northern Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-31T18:59:06.236Z</lastUpdated>
  </row>
  <row>
    <udiDi>06420615711063</udiDi>
    <basicUdiDi>642061571360072BK</basicUdiDi>
    <tradeName>Terveyskaista HOIVA Makrogoli 4000 Suolaton 10x12 g</tradeName>
    <deviceName>MACROGOL</deviceName>
    <manufacturerName>Galena Pharma Oy</manufacturerName>
    <manufacturerSrn>FI-MF-000000588</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>503009</reference>
    <placedOnMarketCountry>Finland</placedOnMarketCountry>
    <lastUpdated>2026-07-31T14:37:55.430Z</lastUpdated>
  </row>
  <row>
    <udiDi>05944732019112</udiDi>
    <basicUdiDi>5944732DEFOAMINGEQ</basicUdiDi>
    <tradeName>05944732019112</tradeName>
    <deviceName>Assista Simeticona Baby, emulsie</deviceName>
    <manufacturerName>Fiterman Pharma SRL</manufacturerName>
    <manufacturerSrn>RO-MF-000001410</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ASSB em50</reference>
    <placedOnMarketCountry>Romania</placedOnMarketCountry>
    <lastUpdated>2026-07-31T13:16:32.661Z</lastUpdated>
  </row>
  <row>
    <udiDi>05904055005179</udiDi>
    <basicUdiDi>5904055002ZSEP</basicUdiDi>
    <tradeName>Ulgix Wzdęcia Baby</tradeName>
    <deviceName>Emulsja doustna z symetykonem ze strzykawką dozującą</deviceName>
    <manufacturerName>Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - Lek S.A.</manufacturerName>
    <manufacturerSrn>PL-PR-000009265</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Not applicable</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-31T10:24:20.143Z</lastUpdated>
  </row>
  <row>
    <udiDi>05904055002871</udiDi>
    <basicUdiDi>5904055001KQ3</basicUdiDi>
    <tradeName>ULGIX WZDĘCIA MAX</tradeName>
    <deviceName>Kapsułki miękkie z symetykonem (Soft capsules with simethicone)</deviceName>
    <manufacturerName>Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - Lek S.A.</manufacturerName>
    <manufacturerSrn>PL-MF-000009264</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>-</reference>
    <placedOnMarketCountry>Poland</placedOnMarketCountry>
    <lastUpdated>2026-07-31T10:24:15.353Z</lastUpdated>
  </row>
  <row>
    <udiDi>05906071004334</udiDi>
    <basicUdiDi>590280270026AT</basicUdiDi>
    <tradeName>Calominal</tradeName>
    <deviceName>Calominal</deviceName>
    <manufacturerName>Aflofarm Farmacja Polska Sp. z o.o.</manufacturerName>
    <manufacturerSrn>PL-MF-000001809</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>N/A</reference>
    <placedOnMarketCountry>Poland</placedOnMarketCountry>
    <lastUpdated>2026-07-31T10:10:56.336Z</lastUpdated>
  </row>
  <row>
    <udiDi>05400951001180</udiDi>
    <basicUdiDi>5400951FBFORTIIBT1B3</basicUdiDi>
    <tradeName>XLS Medical Pro 7</tradeName>
    <deviceName>FAT BINDER FORTE type 1</deviceName>
    <manufacturerName>Omega Pharma International NV</manufacturerName>
    <manufacturerSrn>BE-MF-000007210</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>CT28088</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-31T07:49:26.898Z</lastUpdated>
  </row>
  <row>
    <udiDi>05400951001197</udiDi>
    <basicUdiDi>5400951FBFORTIIBT2B5</basicUdiDi>
    <tradeName>XLS Medical Pro 7</tradeName>
    <deviceName>FAT BINDER FORTE type 2</deviceName>
    <manufacturerName>Omega Pharma International NV</manufacturerName>
    <manufacturerSrn>BE-MF-000007210</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>CT28089</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-31T07:42:28.862Z</lastUpdated>
  </row>
  <row>
    <udiDi>05400951001104</udiDi>
    <basicUdiDi>5400951FBFORTIIBT1B3</basicUdiDi>
    <tradeName>XLS Medical Pro 7 Kapseln</tradeName>
    <deviceName>FAT BINDER FORTE type 1</deviceName>
    <manufacturerName>Omega Pharma International NV</manufacturerName>
    <manufacturerSrn>BE-MF-000007210</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>CT30783</reference>
    <placedOnMarketCountry>Belgium</placedOnMarketCountry>
    <lastUpdated>2026-07-31T07:42:28.056Z</lastUpdated>
  </row>
  <row>
    <udiDi>05061009420010</udiDi>
    <basicUdiDi>506100942ES-CYT-102Z9</basicUdiDi>
    <tradeName>EndoSign® Cell collection device</tradeName>
    <deviceName>EndoSign® Cell collection device</deviceName>
    <manufacturerName>Cyted Ltd</manufacturerName>
    <manufacturerSrn>GB-MF-000035140</manufacturerSrn>
    <authorisedRepresentativeName>Advena Limited</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>MT-AR-000000234</authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0499</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ES-CYT-102</reference>
    <placedOnMarketCountry>Sweden</placedOnMarketCountry>
    <lastUpdated>2026-07-31T06:07:07.165Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778108184</udiDi>
    <basicUdiDi>42517781MD347D7</basicUdiDi>
    <tradeName>DulcoSoft</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>795089</reference>
    <placedOnMarketCountry>Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-30T22:07:42.065Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106234</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1571308</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:38:12.714Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106241</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1571391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.998Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106258</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1571373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.966Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106265</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>572308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.908Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106272</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>572391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.838Z</lastUpdated>
  </row>
</eudamedExport>